ENDRA Life Sciences (NDRA) EBITDA Margin (2016 - 2018)

ENDRA Life Sciences has disclosed EBITDA Margin across 3 years of filings, most recently posting 45960.77% for Q1 2018.

• In Q1 2018, EBITDA Margin changed N/A year-over-year to 45960.77%; the TTM figure through Dec 2018 stood at 146080.47% (down 14476512.0% YoY), while the FY2018 annual figure was 146080.47%, down 14476483.0% from the prior year.
• EBITDA Margin declined to 45960.77% in Q1 2018, from 33526.58% in the prior quarter.
• Over the last five years, EBITDA Margin for NDRA reached as high as 61.85% in Q4 2016 and fell as low as 45960.77% in Q1 2018.
• The 3-year median for EBITDA Margin is 1829.36% (2017), against an average of 16339.19%.
• The widest YoY moves for EBITDA Margin: up 3346474 bps in 2017, down 3346474 bps in 2017.
• A 3-year view of EBITDA Margin shows it stood at 61.85% in 2016, then plunged by 54107 bps to 33526.58% in 2017, then slumped by 37 bps to 45960.77% in 2018.
• According to Business Quant data, EBITDA Margin over the past three periods registered 45960.77%, 33526.58%, and 317.4% for Q1 2018, Q4 2017, and Q3 2017 respectively.